Aknemycin is used topically in the treatment of inflammatory acne vulgaris. The drug is not indicated in the treatment of noninflammatory acne. Therapy of acne vulgaris must be individualized and frequently modified depending on the types of acne lesions which predominate and the response to therapy. Topical anti-infectives, including erythromycin, are generally effective in the treatment of mild to moderate inflammatory acne and are particularly useful in the treatment of mild, papular acne of puberty and early adolescence and papular-pustular acne in adult women.
Generally, a decrease in the number of inflammatory lesions occurs in most patients after 3–8 weeks of topical Aknemycin therapy; however, a decrease in the number of comedones may not occur for several months. Maximum benefit may not occur for up to 12 weeks.